Bruce Belanger

Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

Andrea Wang‐Gillam, Chung‐Pin Li, G. Bodoky et al. · The Lancet · 2015 · 1.2K citations

Medicine, Oncology, Pharmacology +16

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors

Andrea Wang‐Gillam, Richard Hubner, Jens T. Siveke et al. · European Journal of Cancer · 2019 · 328 citations · Full text

Medicine, Oncology, Pharmacology +17

Baseline characteristics and early on-treatment response predict the outcomes of 2years of telbivudine treatment of chronic hepatitis B

Stefan Zeuzem, Edward Gane, Yun‐Fan Liaw et al. · Journal of Hepatology · 2009 · 195 citations

Medicine, Pharmacology, Pharmacotherapy +16

Population Pharmacokinetics of Liposomal Irinotecan in Patients With Cancer

B. Adiwijaya, J. Kim, István Láng et al. · Clinical Pharmacology & Therapeutics · 2017 · 56 citations · Full text

Medicine, Oncology, Pharmacology +13

NAPOLI-1: Randomized Phase 3 Study of MM-398 (NAL-IRI), with or Without 5-Fluorouracil and Leucovorin, Versus 5-Fluorouracil and Leucovorin, in Metastatic Pancreatic Cancer Progressed on or Following Gemcitabine-Based Therapy

Daniel D. Von Hoff, C.P. Li, Andrea Wang‐Gillam et al. · Annals of Oncology · 2014 · 52 citations · Full text

Medicine, Oncology, Pharmacology +14